How is Pemvidutide administered?
This describes how Pemvidutide is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once weekly schedule, generally over trial protocols. Specific dosing is individual and beyond general information, and human evidence for Pemvidutide is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once weekly
- Cycle length: Trial protocols
- Half-life: ~5 days
References
- Pemvidutide for the treatment of NAFLD/NASH, Phase 1b — Altimmune Phase 1b readout, 2023
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study — Harrison SA et al., Journal of Hepatology, 2025
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis — Noureddin M et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Pemvidutide
Last updated 2026-06-15.